Biomarkers and beyond in idiopathic interstitial pneumonia

Poster Discussion
Chairs: M. Wijsenbeek (Rotterdam, Netherlands), N. Hirani (Edinburgh (Edinburgh), United Kingdom)

Adherence to home spirometry among patients with IPF: results from the INMARK trial I. Noth (Virginia, United States of America), T. Maher (London, United Kingdom), K. Johannson (Calgary, Canada), N. Chaudhuri (Manchester, United Kingdom), S. Jouneau (Rennes, France), A. Michael (Farnborough, United Kingdom), K. Rohr (Ingelheim am Rhein, Germany), M. Quaresma (Ingelheim am Rhein, Germany), S. Stowasser (Ingelheim am Rhein, Germany), V. Cottin (Lyon, France)
Differences between ANCA positive and negative lung fibrosis cases without vasculitis N. Mogulkoc (Izmir, Turkey), M. Tas (Izmir, Turkey), Y. Kabasakal (Izmir, Turkey), P. Bishop (Manchester, United Kingdom), S. Littnerová (Brno, Czech Republic), K. Hejduk (Brno, Czech Republic), M. Vašáková (Prague , Czech Republic)
Single-nucleotide polymorphisms within TOLLIP and the efficacy of inhaled N-acetylcysteine therapy in idiopathic pulmonary fibrosis. K. Koyama (Tokushima, Japan), S. Sakamoto (Tokyo, Japan), S. Homma (Tokyo, Japan), S. Sato (Tokushima, Japan), M. Hanibuchi (Tokushima, Japan), Y. Toyoda (Tokushima, Japan), K. Masuda (Okayama, Japan), I. Imoto (Aichi, Japan), T. Isshiki (Tokyo, Japan), S. Miyoshi (Tokyo, Japan), M. Kato (Tokyo, Japan), K. Takahashi (Tokyo, Japan), K. Kataoka (Aichi, Japan), Y. Kondoh (Aichi, Japan), Y. Nishioka (Tokushima, Japan)
Decline in 4-metre gait speed (4MGS) over 6 months is associated with mortality in IPF. C. Nolan (London, United Kingdom), M. Maddocks (London, United Kingdom), T. Maher (London, United Kingdom), S. Patel (London, United Kingdom), R. Barker (London, United Kingdom), S. Jones (London, United Kingdom), J. Walsh (London, United Kingdom), S. Wynne (London, United Kingdom), P. George (London, United Kingdom), P. Cullinan (London, United Kingdom), W. Man (London, United Kingdom)
Using a selective avß6 PET ligand to optimise early phase IPF clinical trials J. Simpson (Stevenage, United Kingdom), A. Kang'Ombe (Stevenage, United Kingdom), M. Costa (Stevenage, United Kingdom), F. Wilson (Stevenage, United Kingdom), W. Fahy (Stevenage, United Kingdom), R. Marshall (Stevenage, United Kingdom), C. Maden (Stevenage, United Kingdom), C. Coello (London, United Kingdom), A. Saleem (London, United Kingdom), D. Fairman (Stevenage, United Kingdom), M. Vahdati-Bolouri (Stevenage, United Kingdom), T. Maher (London, United Kingdom)
Diurnal variation in forced vital capacity in patients with fibrotic interstitial lung disease using home spirometry: the DIVA study K. Moor (Rotterdam, Netherlands), L. Visser (Rotterdam, Netherlands), J. Aerts (Rotterdam, Netherlands), V. Cottin (Lyon, France), M. Wijsenbeek (Rotterdam, Netherlands)
Prognostic impact of radiological findings in unclassifiable interstitial lung diseases S. Torrisi (Heidelberg, Germany), C. Hyldgaard (Aarhus, Denmark), N. Kahn (Heidelberg, Germany), C. Heussel (Heidelberg, Germany), C. Vancheri (Catania, Italy), E. Bendstrup (Aarhus, Denmark), M. Kreuter (Heidelberg, Germany)
Association between exposure to air pollution and mortality in patients with idiopathic pulmonary fibrosis H. Yoon (Seoul, Republic of Korea), S. Kim (Seoul, Republic of Korea), J. Song (Seoul, Republic of Korea)
Clinical significance of serum SP-D as a biomarker for antifibrotics in idiopathic pulmonary fibrosis (IPF): Post hoc analysis of a phase 3 trial of pirfenidone in Japan H. Chiba (Sapporo, Japan), . Ikeda (Sapporo, Japan), A. Azuma (Tokyo, Japan), Y. Kondoh (Seto, Japan), T. Ogura (Yokohama, Japan), Y. Taguchi (Tenri, Japan), M. Ebina (Sendai, Japan), S. Miyazawa (Osaka, Japan), H. Sakaguchi (Osaka, Japan), M. Suga (Kumamoto, Japan), Y. Sugiyama (Shimotsuke, Japan), T. Nukiwa (Sendai, Japan), S. Kudoh (Tokyo, Japan), H. Takahashi (Sapporo, Japan)
Serum high mobility group box 1 is associated with the onset and severity of acute exacerbation of idiopathic pulmonary fibrosis K. Yamaguchi (Hiroshima, Japan), H. Iwamoto (Hiroshima, Japan), S. Sakamoto (Hiroshima, Japan), Y. Horimasu (Hiroshima, Japan), T. Masuda (Hiroshima, Japan), S. Miyamoto (Hiroshima, Japan), T. Nakashima (Hiroshima, Japan), S. Ohshimo (Hiroshima, Japan), K. Fujitaka (Hiroshima, Japan), H. Hamada (Hiroshima, Japan), N. Hattori (Hiroshima, Japan)
Does brain natriuretic peptide (BNP) at baseline influence the effects of nintedanib plus sildenafil in patients with IPF? J. Behr (Munich, Germany), M. Kolb (Hamilton, Ontario, Canada), H. Olschewski (Graz, Austria), J. Song (Seoul , Republic of Korea), F. Luppi (ASST Monza, Italy), B. Schinzel (Ingelheim am Rhein, Germany), S. Stowasser (Ingelheim am Rhein, Germany), M. Quaresma (Ingelheim am Rhein, Germany), F. Martinez (New York , United States of America)
Relationship between body mass index (BMI) and decline in FVC in patients with IPF S. Jouneau (Rennes, France), B. Crestani (Paris, France), R. Thibault (Rennes, France), M. Lederlin (Rennes, France), L. Vernhet (Rennes, France), W. Stansen (Ingelheim am Rhein, Germany), M. Quaresma (Ingelheim am Rhein, Germany), V. Cottin (Lyon, France)
Endothelial cell-derived microparticles as potential biomarkers in chronic interstitial lung diseases T. Neri (Pisa, Italy), L. Tavanti (Pisa, Italy), S. De Magistris (Pisa, Italy), S. Lombardi (Massa, Italy), C. Romei (Pisa, Italy), A. Palla (Pisa, Italy), P. Paggiaro (Pisa, Italy), A. Celi (Pisa, Italy)
Effect of nintedanib on blood biomarkers in patients with IPF in the INMARK trial G. Jenkins (Nottingham , United Kingdom), T. Maher (London, United Kingdom), V. Cottin (Lyon , France), Y. Nishioka (Tokushima, Japan), I. Noth (Charlottesville, Virginia, United States of America), E. White (Ann Arbor, Michigan, United States of America), C. Ittrich (Biberach an der Riss, Germany), C. Diefenbach (Ingelheim am Rhein, Germany), K. Rohr (Ingelheim am Rhein, Germany), S. Stowasser (Ingelheim am Rhein, Germany), M. Selman (Mexico City , Mexico)
Usefulness of electronic nose in detection of Interstitial Lung Diseases (ILD) S. Barril Farre (Lleida, Spain), J. Giner (Barcelona, Spain), J. Merino (Mallorca, Spain), A. Feliu (Barcelona, Spain), P. Millán (Barcelona, Spain), O. Sibila (Barcelona, Spain), D. Castillo (Barcelona, Spain)
Characterization of unique pro-fibrotic T cells resident in the lungs L. Sikkeland (Oslo, Norway), S. Qiao (Oslo, Norway), T. Ueland (Oslo, Norway), T. Sjåheim (Oslo, Norway), J. Kongerud (Oslo, Norway), Ø. Molberg (Oslo, Norway), M. Lund (Oslo, Norway), E. Bækkevold (Oslo, Norway)
Prognostic evaluation of alveolar concentration of nitric oxide, serum periostin and CD59 in patients with idiopathic pulmonary fibrosis P. Cameli (Siena, Italy), E. Bargagli (Siena, Italy), M. D'Alessandro (Siena, Italy), L. Bergantini (Siena, Italy), P. Sestini (Siena, Italy)